This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamamoto, I. Articles by Kuramoto, A. Search for Related Content PubMed PubMed Citation Articles by Yamamoto, I. Articles by Kuramoto, A.

Production of Interleukin 1ß, a Potent Bone Resorbing Cytokine, by Cultured Human Myeloma Cells

Department of Medicine, Kyoto City Hospital, Mibu, Nakagyo, Kyoto, 606 [I. Y.]; Department of Medicine, Research Institute for Nuclear Medicine and Biology, Hiroshima University, Kasuni, Minami, Hiroshima, 734 [M. K., K. I., H. T., H. I., H. A., O. T., M. N., A. K.]; Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyo, Kyoto, 606 [T. S., N. K., K. L., C. S., J. K.]; Laboratories of Cellular Technology, Ohtsuka Pharmaceutical Company, Ltd., Tokushima, 771-01 [Y. O., Y. H.]; and Tokyo University School of Pharmacology, Bunkyo, Tokyo, 110 [M. H., T. O.], Japan

Supernatants of freshly isolated human myeloma cell cultures were examined both for bone-resorbing activity (BRA) in vitro using newborn mouse calvaria, and for identification of the causal substances of the BRA. Eight of 14 culture supernatants of myeloma cells had BRA. All of these BRA-positive supernatants were from patients with marked destructive bone lesions of multiple myeloma. The presence of interleukin 1 (IL-1), especially IL-1ß, was demonstrated in seven of these BRA-positive supernatants but not in BRA-negative supernatants. The concentrations of IL-1ß were high enough to induce bone resorption in the newborn mouse calvaria assay and the BRA was totally abolished by pretreatment of the supernatants with anti-IL-1ß antibody but not with either anti-IL-1 antibody or normal serum. Other bone resorbing cytokines such as tumor necrosis factor or lymphotoxin were not present in high enough concentrations to stimulate bone resorption and their levels did not correlate with the BRA. IL-1ß mRNA was also identified in BRA-positive myeloma cells. These results demonstrate that IL-1ß is the principal agent of BRA present in supernatants of myeloma cell cultures, and also identify a possible role of IL-1ß in destructive bone lesions in patients with multiple myeloma.

¹ To whom requests for reprints should be addressed, at Department of Medicine, Kyoto City Hospital, 1–2 Higashitakada-cho, Mibu, Nakagyo, Kyoto, 604, Japan.

Received 2/ 3/89. Revised 4/25/89. Accepted 5/ 2/89.

This article has been cited by other articles:

				H. Shibata, M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Sano, K.-i. Kitazoe, T. Hashimoto, S. Ozaki, S. Wakatsuki, et al. Malignant B-Lymphoid Cells with Bone Lesions Express Receptor Activator of Nuclear Factor-{kappa}B Ligand and Vascular Endothelial Growth Factor to Enhance Osteoclastogenesis Clin. Cancer Res., September 1, 2005; 11(17): 6109 - 6115. [Abstract] [Full Text] [PDF]

				A. N. Farrugia, G. J. Atkins, L. B. To, B. Pan, N. Horvath, P. Kostakis, D. M. Findlay, P. Bardy, and A. C. W. Zannettino Receptor Activator of Nuclear Factor-{kappa}B Ligand Expression by Human Myeloma Cells Mediates Osteoclast Formation in Vitro and Correlates with Bone Destruction in Vivo Cancer Res., September 1, 2003; 63(17): 5438 - 5445. [Abstract] [Full Text] [PDF]

				M. Q. Lacy, K. A. Donovan, J. K. Heimbach, G. J. Ahmann, and J. A. Lust Comparison of Interleukin-1beta Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Blood, January 1, 1999; 93(1): 300 - 305. [Abstract] [Full Text] [PDF]